Back to search

Article

Evaluation of neutralizing capacity of tixagevimab plus cilgavimab: a case-series study with comparison to a vaccinated population

2023-10-13

Abstract excerpt

AZD7442 (150 mg of tixagevimab plus 150 mg cilgavimab) has been approved for the pre-exposure prophylaxis of COVID-19 and for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who are at increased risk of severe COVID-19. In this study, two patients received AZD7442 for immunoprophylaxis. A cohort of subject who had received the BNT162b2 mRNA COVID‐19 vaccine has been...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8623634c-2c4b-5aae-9f03-e1867dd87351
DOI
10.21203/rs.3.rs-3430872/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Evaluation of neutralizing capacity of tixagevimab plus cilgavimab: a case-series study with comparison to a vaccinated populationDOI 10.21203/rs.3.rs-3430872/v1
Long-term outcomes and neutralising antibody kinetics after Tixagevimab/Cilgavimab prophylaxis in haematological patients: a real-world cohort study in JapanSemantic proximity
Pre-exposure prophylaxis for COVID-19 with Tix-agevimab/Cilgavimab in kidney transplant recipients in the Kraken variant (XBB.1.5) era: A Single-center ExperienceSemantic proximity
Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patientsSemantic proximity
VYD2311 is a promising candidate for passive immunization against COVID-19 in immunocompromised individualsSemantic proximity
Real World Effectiveness of Tixagevimab/cilgavimab (Evusheld) in the Omicron EraSemantic proximity
Immune Response and Reactogenicity After Immunization With a Suboptimal Two-Dose mRNA Vaccine Followed by a Full Vaccination With a Standard mRNA Vaccine Compared to a Prime-Boost Regimen of a Standard mRNA Vaccine: A Multicenter Cohort StudySemantic proximity
Unveiling Protection: A Meta-Analysis of Tixagevimab-Cilgavimab Prophylaxis in 28,950 Transplant Recipients and Immunocompromised Patients Against COVID-19Semantic proximity
Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic DataSemantic proximity
A single intramuscular injection of monoclonal antibody MAD0004J08 induces in healthy adults SARS-CoV-2 neutralising antibody titres exceeding those induced by infection and vaccinationSemantic proximity
Sotrovimab neutralizing SARS-CoV-2: Risk factors for post-infusion clinical eventsSemantic proximity
Breakthrough Covid-19 cases despite tixagevimab and cilgavimab (Evusheld™) prophylaxis in kidney transplant recipientsSemantic proximity
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialSemantic proximity
Select a neighboring publication to make it the new centre.